Paolo Bossi, Head of the Head and Neck Medical Oncology Unit and Associate Professor of Medical Oncology at Humanitas University and Humanitas Cancer Center, shared a post on LinkedIn:
“Grateful to Cancer Research Institute supporting the Aphrodite trial: CD40 agonist to intercept malignant transformation of Oral Potentially Malignant Disorders (OPMD). The trial and its translational correlates will shed light on a new way to reduce the risk of oral cavity cancer.
Humanitas Cancer Center and Humanitas University are the coordinators of the Aphrodite trial.”
More posts featuring Paolo Bossi on OncoDaily.